Drug Profile
Amfetamine controlled release (orally disintegrating tablet) - Aytu BioPharma
Alternative Names: Adzenys XR-ODT; Amfetamine polistirex; Amfetamine XR-ODT - Aytu BioPharma; Amphetamine extended-release - Aytu BioPharma; Amphetamine orally disintegrating tablet - Aytu BioPharma; Amphetamine XR-ODT - Aytu BioPharma; NT-0202Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator Neos Therapeutics
- Developer Aytu BioPharma
- Class Amphetamines; Antipsychotics; Behavioural disorder therapies; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Attention-deficit hyperactivity disorder
Most Recent Events
- 31 Jul 2023 Aytu Biopharma and Medomie Pharma entered into an exclusive collaboration, distribution and supply agreement to commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian
- 22 Mar 2021 Neos Therapeutics has merged with Aytu BioScience to form Aytu BioPharma
- 13 Mar 2020 Neos Therapeutics announces intention to launch amfetamine controlled release for Attention deficit hyperactivity disorder in Puerto Rico in the second quarter of 2020